Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

Finn Edler von EybenGiandomenico RovielloTimo KiljunenChristian UprimnyIrene VirgoliniKalevi KairemoTimo Joensuu

Published in: European journal of nuclear medicine and molecular imaging (2017)

As for patients with mCRPC, treatment with 177Lu-PSMA-617 RTL and 177Lu-PSMA I&T gave better effects and caused fewer adverse effects than third-line treatment.

Keyphrases

pet ct
small cell lung cancer
pet imaging
bone marrow